AI Summary & Key Takeaways
AI InsightAdditionally, theapoptoticmorphologicalchanges were observed in these cells.Conclusions: In conclusion, the obtained results suggest that quercetin could potentially be used as analternative therapeutic strategy in BRCA1 mutant TNBC to overcome acquired BMN 673-resistance.
📌 3 Key Takeaways
Abstract
Objectives: Poly (ADP-ribose) polymerase (PARP) inhibitors have demonstrated an outstanding activity inpatients with BRCA-mutated and wild-type breast cancer. However, the identification of resistance mechanismsto PARP inhibitors is a significant clinical challenge in effective treatment. Thus, new therapeutic strategiesare urgently needed to overcome resistance. The aim of the current study was to explore the potential effect ofquercetin on HCC1937 (BRCA1 mutant) and talazoparib (BMN 673), a PARP inhibitor, resistant HCC1937(HCC1937-R) triple negative breast cancer cells (TNBC).Methods: We firstly generated BMN 673 resistance HCC1937 cells by continuous exposure to BMN 673during 6 months. Then, cells were exposed to the different concentration (0-100 µM) of quercetin and thecytotoxic and apoptotic effects of quercetin on these cells were evaluated by WST-1, Annexin V and dualacridine orange-ethidiumbromide (Et-BR) staining.Results: The cell viability of HCC1937 and HCC1937-R cells reduced to 37.1% and 44.2% at a concentrationof 100 μM, respectively for 48 h (p < 0.01). Apoptotic rates of HCC1937 and HCC1937-R cells treated with100 μM quercetin were nearly 56.0% and 46.0%, respectively (p < 0.01). Additionally, theapoptoticmorphologicalchanges were observed in these cells.Conclusions: In conclusion, the obtained results suggest that quercetin could potentially be used as analternative therapeutic strategy in BRCA1 mutant TNBC to overcome acquired BMN 673-resistance.